Inside Information / Other news releases

PRESS RELEASE - May 8, 2024 – 9:00 am CEST - Montpellier, France - Euronext: MEDCL  

Medincell announces the suspension of listing of its shares on Euronext Paris 

The listing of the Medincell shares on Euronext Paris has been suspended at the request of the Company, pending the publication of a press release. Trading on Euronext Paris will resume tomorrow at the opening of markets.

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO^® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO^® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY™ (BEPO^® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. 

UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals

www.medincell.com

Contacts

David Heuzé

Head of Corporate and Financial Communications, and ESG david.heuze@medincell.com / +33 (0)6 83 25 21 86

Grace Kim

Head of US Financial Strategy & IR

grace.kim@medincell.com / +1 (646) 991-4023

Nicolas Mérigeau Media Relations

medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier Investor Relations France

medincell@newcap.eu / +33 (0)1 44 71 94 94

                                                                                                                                                   1 / 1